The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …

In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …

Introduction A systematic literature review was undertaken to evaluate real-world use of
ceftazidime-avibactam for infections due to aerobic Gram-negative organisms in adults with …

Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range
of serious infections that are often challenging to treat, as this pathogen can express multiple …

Clinicians may use ceftazidime/avibactam in combination with other active agents to treat
infections due to carbapenem-resistant organisms, although no conclusive data support this …

Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment
of serious infections due to gram− negative bacteria (GNB) other than carbapenem-resistant …

Background Clinical experience with ceftazidime-avibactam (CAZ-AVI) for treatment of
infections due to multidrug or extremely resistant (MDR/XDR) Pseudomonas aeruginosa (P …

Background Healthcare-associated infections involving Gram-negative bacteria (GNB) with
difficult-to-treat resistance (DTR) phenotype are associated with impaired patient-centered …

Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) and
carbapenem-resistant Pseudomonas aeruginosa (CRPA) are a growing threat. The …

Ventilator-associated pneumonia (VAP) in critically ill patients with COVID-19 represents a
very huge global threat due to a higher incidence rate compared to non-COVID-19 patients …